Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07223138 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Study to Evaluate the Long-term Safety, Tolerability, and Efficacy of Subcutaneous Sonelokimab in Participants With Psoriatic Arthritis

StatusEnrolling by Invitation
PhasePhase 3
Started
View on ClinicalTrials.gov ↗

Record History

  1. Study sites: 16 to 17v8
  2. Study sites: 14 to 16v7
  3. Trial sites expanded: 10 → 14 locationsv6
  4. Trial sites expanded: 6 → 10 locationsv5
  5. Study sites: 3 to 6v4
Show 2 earlier versionsHide 2 earlier versions
  1. Study sites: 2 to 3v3
  2. Trial status: Not Yet Recruiting to Enrolling by Invitation Study sites: 0 to 2 · Start date changed from estimate of Oct 20, 2025 to Nov 13, 2025v2 Show 2 more changesShow less
    • Study sites: 0 to 2
    • Start date changed from estimate of Oct 20, 2025 to Nov 13, 2025
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This is a study to demonstrate the long-term safety, tolerability and clinical efficacy of sonelokimab in the treatment of patients with psoriatic arthritis who completed a parental study (M1095-PSA-301 or M1095-PSA-302)
Trial Details
NCT Number NCT07223138
Lead Sponsor MoonLake Immunotherapeutics AG
Conditions Arthritis, Psoriatic
Enrollment 1,560 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov